OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer
Name:
mdz250.039.pdf
Size:
70.14Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract
Authors
McNeish, IAMoreno, V
Jayson, Gordon C
Roxburgh, P
Ginesta, MPB
Garcia-Donas, J
Torres, AA
Michael, A
Brown, R
Krige, D
Bendall, J
Di Genova, G
McElwaine-Johnn, H
Affiliation
Department of Surgery and Cancer, Imperial College London, LondonIssue Date
2019
Metadata
Show full item recordCitation
McNeish IA, Moreno V, Jayson G, Roxburgh P, Ginesta MPB, Garcia-Donas J, et al. 1031P OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer. Annals of Oncology. 2019;30(Supplement_5):421.Journal
Annals of OncologyDOI
10.1093/annonc/mdz250.039Additional Links
https://dx.doi.org/10.1093/annonc/mdz250.039Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz250.039